Full Press Release Details
argenx announces launch of proposed initial public offering in the United States.
ARGX
argenx announces launch of proposed initial public offering in the United States
Key Takeaway: argenx announces launch of proposed initial public offering in the United States
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis